TY - JOUR
T1 - Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer
AU - Goldberg, Michael R.
AU - Heimbrook, David C.
AU - Russo, Paul
AU - Sarosdy, Michael F.
AU - Greenberg, Richard E.
AU - Giantonio, Bruce J.
AU - Linehan, W. Marston
AU - Walther, M.
AU - Fisher, Hugh A.G.
AU - Messing, Edward
AU - Crawford, E. David
AU - Oliff, Allen I.
AU - Pastan, Ira H.
PY - 1995/1
Y1 - 1995/1
N2 - Transforming growth factor α-Pseudomonas exotoxin-40 (TP40) is a hybrid fusion protein that selectively binds to cancer cells that express the epidermal growth factor receptor, TP40 is then internalized and kills these cells by virtue of its Pseudomonas exotoxin-derived domains. We studied the safety and short-term antitumor activity of intravesical TP40 in 43 patients with refractory superficial bladder cancer. These patients had resected T(a)/T1 disease (n = 19), visible T(a) or T1 lesions (n = 11), or carcinoma in situ (n = 13). Patients were treated with increasing dose levels of TP40 at 0.15, 0.3, 0.6, 1.2, 2.4, 4.8, or 9.6 mg/week for 6 weeks and evaluated by comparing pretreatment and posttreatment cystoscopic examinations, cytology, and histopathology. All TP40 doses were well tolerated. No evidence of antitumor activity was seen in any of the patients with T(a) or T1 lesions, However, 8 of 9 patients with evaluable carcinoma in situ were judged by histopathology of multiple biopsy specimens to exhibit clinical improvement following TP40 therapy, In most of these responsive patients, cystoscopic examination supported the histopathological findings, although cytology of urine and bladder washings persistently demonstrated malignant cells. Therefore, TP40 appears to be a well-tolerated biological agent that may prove to have utility in treating carcinoma in situ of the bladder.
AB - Transforming growth factor α-Pseudomonas exotoxin-40 (TP40) is a hybrid fusion protein that selectively binds to cancer cells that express the epidermal growth factor receptor, TP40 is then internalized and kills these cells by virtue of its Pseudomonas exotoxin-derived domains. We studied the safety and short-term antitumor activity of intravesical TP40 in 43 patients with refractory superficial bladder cancer. These patients had resected T(a)/T1 disease (n = 19), visible T(a) or T1 lesions (n = 11), or carcinoma in situ (n = 13). Patients were treated with increasing dose levels of TP40 at 0.15, 0.3, 0.6, 1.2, 2.4, 4.8, or 9.6 mg/week for 6 weeks and evaluated by comparing pretreatment and posttreatment cystoscopic examinations, cytology, and histopathology. All TP40 doses were well tolerated. No evidence of antitumor activity was seen in any of the patients with T(a) or T1 lesions, However, 8 of 9 patients with evaluable carcinoma in situ were judged by histopathology of multiple biopsy specimens to exhibit clinical improvement following TP40 therapy, In most of these responsive patients, cystoscopic examination supported the histopathological findings, although cytology of urine and bladder washings persistently demonstrated malignant cells. Therefore, TP40 appears to be a well-tolerated biological agent that may prove to have utility in treating carcinoma in situ of the bladder.
KW - Aged
KW - Antineoplastic Agents/adverse effects
KW - Carcinoma in Situ/drug therapy
KW - Dose-Response Relationship, Drug
KW - Exotoxins/adverse effects
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Neoplasm Staging
KW - Transforming Growth Factor alpha/adverse effects
KW - Urinary Bladder Neoplasms/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=0028969845&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:A1995RJ52300008&DestLinkType=FullRecord&DestApp=WOS
M3 - Article
C2 - 9815887
SN - 1078-0432
VL - 1
SP - 57
EP - 61
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 1
ER -